Insider · CIK 0001829252

Garg Pushkal

Reports to the SEC for 2 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001829252

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-05	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−654 sh	$322.33	−$211K	20,443
2026-03-05	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−740 sh	$323.55	−$239K	19,703
2026-03-05	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−510 sh	$324.59	−$166K	19,193
2026-03-05	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−500 sh	$326.08	−$163K	18,693
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−106 sh	$319.03	−$33.8K	23,300
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−102 sh	$320.01	−$32.6K	23,198
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−215 sh	$320.81	−$69K	22,983
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−289 sh	$321.82	−$93K	22,694
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−350 sh	$323.01	−$113K	22,344
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−767 sh	$323.84	−$248K	21,577
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−272 sh	$324.88	−$88.4K	21,305
2026-03-04	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−208 sh	$325.67	−$67.7K	21,097
2026-03-03	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−355 sh	$316.74	−$112K	24,826
2026-03-03	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−317 sh	$319.06	−$101K	24,509
2026-03-03	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−640 sh	$320.48	−$205K	23,869
2026-03-03	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−463 sh	$321.50	−$149K	23,406
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.A Award	EVP Chief R&D	AAward	+4,769 sh	—	—	26,898
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−50 sh	$323.62	−$16.2K	26,848
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−97 sh	$324.65	−$31.5K	26,751
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−277 sh	$325.63	−$90.2K	26,474
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−421 sh	$326.81	−$138K	26,053
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−353 sh	$327.67	−$116K	25,700
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−107 sh	$328.71	−$35.2K	25,593
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−182 sh	$329.71	−$60K	25,411
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−87 sh	$330.85	−$28.8K	25,324
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−101 sh	$331.93	−$33.5K	25,223
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−42 sh	$332.64	−$14K	25,181
2026-03-02	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	EVP Chief R&D	AAward	+10.5K sh	—	—	10,480
2026-02-27	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Chief R&D	MExercise/Conversion	+1,908 sh	—	—	26,756
2026-02-27	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−127 sh	$328.92	−$41.8K	26,629
2026-02-27	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−2,259 sh	$330.73	−$747K	24,370
2026-02-27	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−1,159 sh	$331.49	−$384K	23,211
2026-02-27	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−942 sh	$332.48	−$313K	22,269
2026-02-27	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−140 sh	$334.39	−$46.8K	22,129
2026-02-27	ALNYALNYLAM PHARMACEUTICALS, INC. · Restricted Stock UnitsM Exercise/Conversion	EVP Chief R&D	MExercise/Conversion	−1,908 sh	—	—	0
2026-02-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−2,242 sh	$310.08	−$695K	24,848
2026-02-12	ALNYALNYLAM PHARMACEUTICALS, INC.A Award	EVP Chief R&D	AAward	+4,579 sh	—	—	27,090
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−39 sh	$353.95	−$13.8K	23,982
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−42 sh	$355.16	−$14.9K	23,940
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−41 sh	$356.09	−$14.6K	23,899
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−96 sh	$357.17	−$34.3K	23,803
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−123 sh	$358.18	−$44.1K	23,680
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−85 sh	$359.14	−$30.5K	23,595
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−155 sh	$360.22	−$55.8K	23,440
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−98 sh	$361.45	−$35.4K	23,342
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−73 sh	$362.38	−$26.5K	23,269
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−47 sh	$363.55	−$17.1K	23,222
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−199 sh	$364.83	−$72.6K	23,023
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−220 sh	$365.56	−$80.4K	22,803
2026-01-12	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	EVP Chief R&D	SSale	−50 sh	$366.41	−$18.3K	22,753

Recent filings

Accepted (ET)
Mar 64
Garg Pushkal0001735276-26-000063
SEC(opens sec.gov)
Mar 44
Garg Pushkal0001735276-26-000052
SEC(opens sec.gov)

Companies

Address

675 WEST KENDALL STREET HENRI A. TERMEER SQUARE

CAMBRIDGE, MA, 02142